BioPharmSignal logoBioPharmSignal

Biotech News

ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process

ADMA Biologics (ADMA)ADMA BiologicsCompany update

Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield No Thromboembolic Events Were Reported for ADMA IVIG Products Manufactured Using the Optimized Process During the Postmarketing Surveillance Period Evaluated

Related news

ADMAADMA Biologics2026-11-04 21:05 EST

ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-10-28 11:00 EST

ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026

ALVOAlvotech2026-10-06 20:37 EST

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

ALVOAlvotech2026-10-05 08:00 EST

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

RHHBYRoche Holdings AG2026-10-01 06:00 EST

Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions

RHHBYRoche Holdings AG2026-08-20 15:45 EST

Roche’s US subsidiary Genentech announces manufacturing expansion in the United States

ENTXEntera Bio2026-04-14 12:45 EST

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

View all latest news

ADMA Biologics

Plasma-Derived Biologics ADMA Biologics is a vertically integrated U.S. manufacturer and marketer of plasma-derived immunoglobulin therapies for immunodeficient patients and people at risk of infection. ASCENIV ASCENIV is an intravenous immunoglobulin enriched with antibodies against respiratory syncytial virus. It is positioned for...

Recent company news

ADMAADMA Biologics2026-11-04 21:05 EST

ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-10-28 11:00 EST

ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026

ADMAADMA Biologics2026-10-15 11:00 EST

ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process

ADMAADMA Biologics2026-08-05 20:05 EST

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-07-29 11:00 EST

ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026

Stock data

Close
13.21 USD
Market cap
1.76B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States